SEC filing record
Primary Source · SEC.gov

Lomond Therapeutics Holdings, Inc.

2024 vintageSecurities Exchange Act of 1934Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalExchange Act deregistrationForm 15-12G · 2026-07-105 events: 1 exchange act deregistration, 1 sold increased, 1 investors increasedLast filing 2026-07-10

Raised

$54M

Investors

28

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Lomond Therapeutics Holdings, Inc. is an entity organized in Delaware that first filed a Form D on November 18, 2024 and most recently amended it on July 10, 2026. The offering claims Securities Exchange Act of 1934. Lomond Therapeutics Holdings, Inc. reported $53,915,492 sold from 28 investors as of the Form D filed July 10, 2026. The Form D names Raymond James & Associates, Inc. (CRD 000000705), associated with None; Wedbush & Co., LLC (CRD 000328492), associated with None as recipients of sales compensation soliciting in all states. The issuer's address of record is C/O Lomond Therapeutics Holdings, Inc., 8 the Green Ste 8490, Dover, DE 19901.

EDGAR Filing Data

Form 15 / Schedule TO — Primary Source

View on SEC.gov
CIK Number0001900520
Entity NameLomond Therapeutics Holdings, Inc.
ExemptionSecurities Exchange Act of 1934
Entity Type—
Jurisdiction of OrganizationDelaware
Issuer AddressC/O Lomond Therapeutics Holdings, Inc., 8 the Green Ste 8490, Dover, DE 19901
Phone(561) 464-2841
Former NamesVenetian-1 Acquisition Corp. (until October 28, 2024)
Industry / Fund Type—
Securities Type—
First Sale Date—
Filing DateJuly 10, 2026
Accession Number0001213900-26-077133
Total Offering Amount$63,915,492
Total Amount Sold$53,915,492
Total Investors28
Minimum Investment$0 (no stated minimum)
Offering Duration—
State (Issuer Address)DE
Amendment Count3 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

5

latest Jul 10, 2026

Critical / warning

0 / 1

3 watch · 1 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

1

lapsed

Latest event Exchange act deregistration · Jul 10, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 5 filing events with values and deltas, latest 2026-07-10, and alerts on the next one
  • 1 offering timeline: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Iain Dukes

Executive Officer, Director · Dover, DE

Nikolay Savchuk

Executive Officer, Director · Dover, DE

Carl Gordon

Director · Dover, DE

Eddie Rodriguez

Director · Dover, DE

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Raymond James & Associates, Inc.CRD 000000705 on BrokerCheck

Associated broker-dealer: None · St. Petersburg, FL · Soliciting in all states

Wedbush & Co., LLCCRD 000328492 on BrokerCheck

Associated broker-dealer: None · San Francisco, CA · Soliciting in all states and outside the United States

Questions About Lomond Therapeutics Holdings, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Lomond Therapeutics Holdings, Inc.?

Lomond Therapeutics Holdings, Inc. is an issuer that filed a Form D with the SEC on July 10, 2026. The filing claims Securities Exchange Act of 1934.

Is Lomond Therapeutics Holdings, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Lomond Therapeutics Holdings, Inc. filed a Form D with the SEC on July 10, 2026 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $53,915,492 sold to 28 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Lomond Therapeutics Holdings, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Lomond Therapeutics Holdings, Inc. claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Lomond Therapeutics Holdings, Inc. raised?

Lomond Therapeutics Holdings, Inc. reported $53,915,492 sold from 28 investors as of the Form D filed July 10, 2026.

Who is selling Lomond Therapeutics Holdings, Inc. and how are they paid?

The Form D names Raymond James & Associates, Inc. (CRD 000000705), associated with None; Wedbush & Co., LLC (CRD 000328492), associated with None as recipients of sales compensation soliciting in all states.

Who is behind Lomond Therapeutics Holdings, Inc.?

The Form D lists 4 related persons: Iain Dukes, executive officer, director; Nikolay Savchuk, executive officer, director; Carl Gordon, director; Eddie Rodriguez, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Lomond Therapeutics Holdings, Inc. located?

The issuer's address on its SEC filings is C/O Lomond Therapeutics Holdings, Inc., 8 the Green Ste 8490, Dover, DE 19901. Its phone number of record is 561 464 2841. It is organized under the laws of Delaware.

How long is the Lomond Therapeutics Holdings, Inc. offering open?

An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.